Incanthera PLC (AQSE:INC) has landed its second production order for 250,000 units with Marionnaud AG, part of the Watsons Group.
The company, which is focused on innovative technologies in dermatology, highlighted that it follows a previous increase in its first production order from 50,000 to 100,000 units, which is anticipated to generate revenues of approximately £4 million.
This new order aims to meet the anticipated demand in both the European and Asian markets.
It now means that Incanthera projects its revenues for the current financial year to exceed £10 million, which is expected to help the company achieve profitability.
"It is fantastic to bring this further positive update to the market,” Incanthera chair Tim McCarthy said in a statement.
“This clearly evidences the confidence and anticipation with which Incanthera, and its Swiss subsidiary, Skin + CELL A.G. is managing the production order cycle, in close coordination with Marionnaud, as the teams work collaboratively towards the launch and roll out of Skin + CELL in Europe.”
McCarthy added: “The essential infrastructure and framework that the team established for the commercial deal announcement in December 2023 is now in full operation as we ramp up the production orders and prepare for launch.
“The resulting revenues generated to Incanthera will allow us to further bolster our inventory capacity and ongoing commercial operational model, thereby driving revenue growth and, in turn, increasing the value of our company and the capacity for returns to shareholders."